Intellegens, a company applying machine learning (ML) to accelerate R&D, has secured a £1.6 million grant from Innovate UK to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI), the two-year project will augment and validate the company’s ML technology, Alchemite, as a tool to enhance productivity and yields of oligonucleotide therapeutic manufacture through performance prediction and optimization of quality control stra...